Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?

Surgery Partners (SGRY) jumped 15.7% after completing the sale of its Idaho Falls facilities to Intermountain Health for $797 million in gross proceeds. The divestiture marks a significant liquidity event for the ambulatory surgical center operator.

Analyst sentiment shifted following the transaction. The consensus earnings-per-share estimate for the upcoming quarter climbed 40% over the last 30 days. However, SGRY faces near-term earnings headwinds: analysts project a 30.8% year-over-year decline in quarterly earnings, even as revenue is expected to grow 4.3%.

The stock carries a Zacks Rank #3 (Hold) rating, suggesting analysts see the shares as fairly valued at current levels despite the recent pop.

The $797 million in gross proceeds gives management considerable flexibility for debt reduction, share repurchases, or redeployment into higher-margin facilities. The market's 15.7% reaction suggests investors view the sale price as favorable, though the forward earnings decline indicates operational challenges persist elsewhere in the portfolio.